✉news ScienceBiology first seen 1 d ago, last 1 d ago, peak #37
Whole-Genome Sequencing Probes Bleomycin Lung Injury in Low-Risk Patients
Original: Whole-Genome Sequencing Explores Why Low-Risk Patients Develop Bleomycin Lung Injury
Researchers are using whole-genome sequencing to investigate why some patients classified as low-risk still develop bleomycin-induced lung injury, a serious side effect of the chemotherapy drug. The work aims to uncover genetic variants that predispose individuals to pulmonary toxicity, which could help clinicians better identify vulnerable patients before treatment and guide safer use of bleomycin in cancer care.
Why now: Genetic research offering a potential explanation for unpredictable drug-induced lung damage naturally draws attention from clinicians and patients concerned about chemotherapy side effects.
bleomycinwhole-genome sequencing
Evidence
- Whole-Genome Sequencing Explores Why Low-Risk Patients Develop Bleomycin Lung Injury · Bioengineer.org
API: https://socialmediatrends-api.osmike.com/v1/trends/4200466